Cisplatin Treatment Options in United Kingdom (Updated 8/25)

A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer

NCT00887549

Completed

Thymidylate synthase (TS) is a substance the body produces naturally. The purpose of this research is to determine if there is a link between TS production and how well patients respond to treatment of non-squamous non-small cell lung cancer (NSCLC). The aim for the future is that doctors could have a better understanding in advance about which patients might respond well to pemetrexed based on how much TS they produce.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/07/2012

Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dublin, Not set +13 locations

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dublin, Not set

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Derby, Derbyshire

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Exeter, Devon

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maidstone, Kent

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Preston, Lancashire

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, Merseyside

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Northwood, Middlesex

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scunthorpe, North Lincolnshire

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belfast, Northern Ireland

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nottingham, Nottinghamshire

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aberdeen, Scotland

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wolverhampton, West Midlands

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grimsby, Not set

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, Not set

Conditions: Non-Small Cell Lung Cancer

Register for Updates

Learn More ›

Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents

NCT00147160

Completed

The purpose of this study is to determine whether the combination of Temozolomide and Cisplatinum is effective in the treatment of malignant glial tumours of children and adolescents

Gender:

ALL

Ages:

Between 4 years and 21 years

Trial Updated:

04/10/2012

Locations: Institut Gustave-Roussy, Villejuif, Not set +1 locations

Conditions: Glioma

Register for Updates

Learn More ›

Combination Chemotherapy in Treating Men With Germ Cell Cancer

NCT00003643

Unknown

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy may be more effective for germ cell cancer. PURPOSE: This randomized phase II/III trial is studying two different regimens of combination chemotherapy and comparing how well they work in treating men with germ cell cancer.

Gender:

MALE

Ages:

Between 16 years and 50 years

Trial Updated:

03/05/2012

Locations: Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital, Vienna, Not set +68 locations

Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital, Vienna, Not set

Institut Jules Bordet, Brussels, Not set

Universitair Ziekenhuis Antwerpen, Edegem, Not set

U.Z. Gasthuisberg, Leuven, Not set

Aarhus Universitetshospital - Aarhus Sygehus, Aarhus, Not set

Rigshospitalet - Copenhagen University Hospital, Copenhagen, Not set

Centre Regional Francois Baclesse, Caen, Not set

Institut Claudius Regaud, Toulouse, Not set

Institut Gustave Roussy, Villejuif, Not set

Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Not set

Universitaetsklinikum Bonn, Bonn, Not set

St. Johannes Hospital - Medical Klinik II, Duisburg, Not set

Universitaetsklinikum Essen, Essen, Not set

Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet, Greifswald, Not set

Allgemeines Krankenhaus Hagen, Hagen, Not set

Universitaetsklinikum Halle, Halle, Not set

University Medical Center Hamburg - Eppendorf, Hamburg, Not set

Universitaetsklinikum des Saarlandes, Homburg, Not set

Klinikum Kassel, Kassel, Not set

Klinikum der Stadt Ludwigshafen am Rhein, Ludwigshafen am Rhein, Not set

Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg, Magdeburg, Not set

Klinikum der Stadt Mannheim, Mannheim, Not set

Universitaetsklinikum Giessen und Marburg GmbH - Marburg, Marburg, Not set

Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster, Muenster, Not set

Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Not set

Klinikum Nuernberg - Klinikum Nord, Nuremberg, Not set

Klinikum der Universitaet Regensburg, Regensburg, Not set

Klinikum Schwerin, Schwerin, Not set

Southwest German Cancer Center at Eberhard-Karls-University, Tuebingen, Not set

National Institute of Oncology, Budapest, Not set

Assaf Harofeh Medical Center, Zerifin, Not set

Ospedale di Circolo e Fondazione Macchi, Varese, Not set

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Not set

Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Not set

Leiden University Medical Center, Leiden, Not set

Universitair Medisch Centrum St. Radboud - Nijmegen, Nijmegen, Not set

University Medical Center Rotterdam at Erasmus Medical Center, Rotterdam, Not set

Daniel Den Hoed Cancer Center at Erasmus Medical Center, Rotterdam, Not set

University Medical Center Utrecht, Utrecht, Not set

Norwegian Radium Hospital, Oslo, Not set

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology - Warsaw, Warsaw, Not set

National Cancer Institute - Bratislava, Bratislava, Not set

Hospital de la Santa Cruz i Sant Pau, Barcelona, Not set

Vall d'Hebron University Hospital, Barcelona, Not set

Institut Catala D'Oncologia, Barcelona, Not set

Hospital Universitario San Carlos, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Virgen de la Victoria, Malaga, Not set

Hospital Sant Joan de Reus, Reus, Not set

Hospital Universidad Virgen Del Rocio, Sevilla, Not set

Hospital Universitario La Fe, Valencia, Not set

Hospital Clinico Universitario Lozano Blesa, Zaragoza, Not set

Addenbrooke's Hospital, Cambridge, England

Gloucestershire Oncology Centre at Cheltenham General Hospital, Cheltenham, England

Leeds Cancer Centre at St. James's University Hospital, Leeds, England

Saint Bartholomew's Hospital, London, England

University College Hospital - London, London, England

Christie Hospital, Manchester, England

Nottingham City Hospital NHS Trust, Nottingham, England

Rosemere Cancer Centre at Royal Preston Hospital, Preston, England

Berkshire Cancer Centre at Royal Berkshire Hospital, Reading, England

Cancer Research Centre at Weston Park Hospital, Sheffield, England

Royal South Hants Hospital, Southampton, England

Royal Marsden - Surrey, Sutton, England

Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, England

Aberdeen Royal Infirmary, Aberdeen, Scotland

Western Infirmary, Glasgow, Scotland

Gartnavel General Hospital, Glasgow, Scotland

Velindre Cancer Center at Velindre Hospital, Cardiff, Wales

Conditions: Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor

Register for Updates

Learn More ›

Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

NCT00020696

Completed

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining tirapazamine with cisplatin in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.

Gender:

FEMALE

Ages:

All

Trial Updated:

01/07/2012

Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +53 locations

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California

Community Hospital of Los Gatos, Los Gatos, California

Chao Family Comprehensive Cancer Center, Orange, California

University of Colorado Cancer Center, Denver, Colorado

Walter Reed Army Medical Center, Washington, District of Columbia

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois

University of Chicago Cancer Research Center, Chicago, Illinois

Indiana University Cancer Center, Indianapolis, Indiana

Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa

Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland

Radiation Oncology Branch, Bethesda, Maryland

Tufts University School of Medicine, Boston, Massachusetts

University of Massachusetts Memorial Medical Center, Worcester, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

University of Minnesota Cancer Center, Minneapolis, Minnesota

Mayo Clinic Cancer Center, Rochester, Minnesota

University of Mississippi Medical Center, Jackson, Mississippi

Ellis Fischel Cancer Center - Columbia, Columbia, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Cooper Hospital/University Medical Center, Camden, New Jersey

Cancer Center of Albany Medical Center, Albany, New York

State University of New York Health Science Center at Brooklyn, Brooklyn, New York

Roswell Park Cancer Institute, Buffalo, New York

North Shore University Hospital, Manhasset, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina

Duke Comprehensive Cancer Center, Durham, North Carolina

Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina

Barrett Cancer Center, The University Hospital, Cincinnati, Ohio

Ireland Cancer Center, Cleveland, Ohio

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio

University of Oklahoma College of Medicine, Oklahoma City, Oklahoma

Abington Memorial Hospital, Abington, Pennsylvania

Milton S. Hershey Medical Center, Hershey, Pennsylvania

University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

Medical University of South Carolina, Charleston, South Carolina

Brookview Research, Inc., Nashville, Tennessee

Simmons Cancer Center - Dallas, Dallas, Texas

University of Texas - MD Anderson Cancer Center, Houston, Texas

Fletcher Allen Health Care - Medical Center Campus, Burlington, Vermont

Cancer Center at the University of Virginia, Charlottesville, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

Tacoma General Hospital, Tacoma, Washington

Australia New Zealand Gynaecological Oncology Trials Group, Camperdown, New South Wales

Tom Baker Cancer Center - Calgary, Calgary, Alberta

Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario

University of Birmingham, Birmingham, England

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer

Register for Updates

Learn More ›

CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy

NCT00122772

Completed

The purpose of this trial is to study clinical effects of two/four high dose rate (HDR) brachytherapy applications and teletherapy with or without weekly cisplatin in cervix cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

10/13/2011

Locations: University of Vienna; Department of Radiotherapy and Radiobiology, Vienna, Not set +10 locations

Conditions: Cervix Cancer

Register for Updates

Learn More ›

Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)

NCT00174772

Completed

Primary Objective: * To evaluate the toxicity/safety profile of docetaxel/cisplatin induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by consolidation docetaxel/cisplatin in patients with locally advanced unresectable NSCLC (stage IIIA- multiple cN2 or IIIB). Secondary Objective: * To estimate efficacy parameters in overall response rate, progression free survival and 1 year survival for each of the two above mentioned arms.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

02/15/2010

Locations: Sanofi-Aventis Administrative Office, Diegem, Not set +7 locations

Conditions: Lung Neoplasms

Register for Updates

Learn More ›

A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

NCT00301301

Completed

There has been considerable international /national interest in the GEM-P regimen for treatment of patients with relapsed/refractory lymphoma. Currently, there is no accepted standard therapy for these patients. Since the publication of our experience with this regimen (Study with CCR ethics number 1857 closed to recruitment in July 2003:Ng M, Waters J, Cunningham D et al, Br J Cancer 2005;92:1352-7), we have treated relapsed/refractory lymphoma patients with this regimen and would like to under... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/11/2010

Locations: Royal Marsden NHS trust, Sutton, Surrey

Conditions: Non-Hodgkins Lymphoma

Register for Updates

Learn More ›

Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma

NCT00220103

Completed

To investigate the efficacy and safety of epirubicin, cisplatin and capecitabine as neoadjuvant therapy prior to radical resection in patients with newly diagnosed operable oesophageal adenocarcinoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/15/2009

Locations: Royal Marsden NHS Foundation Trust, Sutton, Surrey

Conditions: Adenocarcinoma of Oesophagus

Register for Updates

Learn More ›

Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus

NCT00220129

Completed

This is a study to investigate the efficacy and safety of epirubicin, cisplatin and capecitabine (ECX) as neoadjuvant therapy prior to radical chemoradiotherapy using capecitabine and cisplatin as radio-sensitisers in patients with newly diagnosed localized squamous cell carcinoma of the oesophagus.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/15/2009

Locations: Royal Marsden Hospital, Sutton, Surrey

Conditions: Oesophageal Carcinoma

Register for Updates

Learn More ›

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

NCT00255476

Completed

The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/22/2009

Locations: Research Site, London, Not set

Conditions: Squamous Cell Cancer, Cancer of Head and Neck

Register for Updates

Learn More ›

Cisplatin Treatment Options in United Kingdom

Match to Clinical Trials